Serum C-C motif chemokine ligand 17 as a predictive biomarker for the progression of non-idiopathic pulmonary fibrosis interstitial lung disease

Table 2 Baseline characteristics at the time of blood collection of the validation cohort

	Non-IPF-ILD^‡
	CCL17 low	CCL17 high	P value
No. of subjects	86	68	-
Age (years)	72 (67–76)	71 (62–77)	0.55
Sex (male)	42 (49%)	39 (57%)	0.33
Smoking history (yes)	45 (52%)	35 (51%)	1.00
Corticosteroid (yes)	21 (24%)	24 (35%)	0.16
Immunosuppressive agents (yes)	11 (13%)	11 (16%)	0.65
Antifibrotic therapy (yes)	2 (2.3%)	2 (2.9%)	1.00
Classification of ILD
INSIP^‡‡	26 (30%)	31 (46%)	0.065
CTD-ILD^§§	30 (35%)	17 (25%)	0.22
Unclassifiable ILD	29 (34%)	15 (22%)	0.15
FHP^llll	1 (1%)	5 (7%)	0.088
Pulmonary function tests
%FVC^‡‡‡	88.2 (73.2–101.0)	74.1 (59.8–89.9)	*0.00070
%DLco^§§§	70.6 (46.7–84.4)	57.2 (37.3–72.2)	*0.0081
ILD-GAP^llllll index			0.83
0–1	39 (45%)	29 (43%)	-
2–3	31 (36%)	28 (41%)	-
4–5	6 (7%)	6 (9%)	-
6–8	1 (1%)	2 (3%)	-
N/A	9 (10%)	3 (4%)	-
Follow up time (months)	59.7 (33.5–60.0)	34.5 (20.1–60.0)	*0.0049

Data are presented as the median (interquartile range) or number of patients (percentage). Differences in the two groups were assessed by the Mann-Whitney U test or Fisher’s exact test. *, P < 0.05
^†idiopathic pulmonary fibrosis; ^‡interstitial lung disease; ^§not available; ^lltotal periostin; ^††C-C motif chemokine ligand 17; ^‡‡idiopathic nonspecific interstitial pneumonia; ^§§connective tissue disease-interstitial lung disease; ^llllfibrotic hypersensitivity pneumonitis; ^†††pleuroparenchymal fibroelastosis; ^‡‡‡%forced vital capacity; ^§§§%diffusing capacity for carbon monoxide; ^llllllgender age physiology

ISSN: 1465-993X